Original Research
Published on 18 Feb 2019
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2019.00057
- 6,150 views
- 30 citations




